Drug Trial Radar · NCT05685602
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
43
Planned (sponsor's estimate)
Start
Jun 12, 2023
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Biopsy ProcedureProcedure
Undergo tumor biopsies
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo a CT scan
EmavusertibBiological
Given PO
Gemcitabine HydrochlorideDrug
Given IV
Nab-paclitaxelDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity rateTime frame: Up to 1 year
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
UCHealth University of Colorado Hospital
Aurora, Colorado
Northwestern University
Chicago, Illinois
Memorial Hospital East
Shiloh, Illinois
University of Kentucky/Markey Cancer Center
Lexington, Kentucky
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center-South County
St Louis, Missouri
Siteman Cancer Center at Christian Hospital
St Louis, Missouri
NYU Langone Hospital - Long Island
Mineola, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.